Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-100: Pembrolizumab in Recurrent Ovarian Cancer
NCT02674061Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Merck & Co.. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02674061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674061.